ARTICLE | Clinical News
ATL-1251 Renzapride: Start Phase I trial
December 18, 2000 8:00 AM UTC
Alizyme plc (LSE:AZM), Cambridge, U.K. Product: ATL-1251 Renzapride Business: Autoimmune/Inflammation Therapeutic category: Receptor agonist, Receptor antagonist Target: 5-HT serotonin receptors Desc...